CFM
CRNX icon

Catalyst Funds Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Catalyst Funds Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000
Closed -$46.8K – 1249
2024
Q1 		$46.8K Buy
+1,000
New +$39.1K 0.01% 578

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Catalyst Funds Management's CRNX Position: Q2 2024 in Review

Catalyst Funds Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2024, closing a stake of 1,000 shares — an estimated $46.8K sold.

Catalyst Funds Management first reported a position in CRNX in Q1 2024 and held it in 1 quarter. The position peaked at $46.8K in Q1 2024. 234 funds tracked by Wall St. Rank hold CRNX as of Q2 2024.

  • Catalyst Funds Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,000 Crinetics Pharmaceuticals shares in Q2 2024, an estimated $46.8K.
  • Catalyst Funds Management first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Crinetics Pharmaceuticals position peaked at $46.8K in Q1 2024.
  • 234 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.